Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A by Cippà, Pietro et al.
ORIGINAL PAPER
Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A
Pietro E. Cippa` • Jivko Kamarashev •
Jin Chen • Anna K. Kraus • Stephan Segerer •
Laurence Feldmeyer • Thomas Fehr
Published online: 4 December 2012
 Springer Science+Business Media New York 2012
Abstract Survival of lymphocytes and melanocyte stem
cells critically depends on B cell lymphoma 2 (Bcl-2). In
T lymphocytes, a basal calcineurin activity maintains Bcl-2
expression in naı¨ve cells, and the activation of the calci-
neurin pathway orchestrates the regulation of the intrinsic
apoptosis pathway after antigen recognition. Therefore,
calcineurin inhibitors might potentiate the pro-apoptotic
effect of pharmacological Bcl-2 inhibitors on lymphatic
cells. In vitro, a reduced Bcl-2 expression in lymphocytes
exposed to calcineurin inhibitors increased their sensitivity
to the small molecule Bcl-2 inhibitor ABT-737. This corre-
lated with an augmented pro-apoptotic activity of ABT-737
on lymphocytes in combination with cyclosporine A in naı¨ve
mice in vivo. Interestingly, similar processes were observed
in melanocytes. ABT-737 induced a fur depigmentation at
the site of injection, and this effect was expanded to a gen-
eralized depigmentation in combination with cyclosporine
A. Thus, inhibiting calcineurin increases the pro-apoptotic
potency of ABT-737 in cells depending on Bcl-2 for sur-
vival. The increased efficacy of Bcl-2 inhibitors in combi-
nation with cyclosporine A might be relevant to exploit their
anti-neoplastic and immuno-modulatory properties.
Keywords Bcl-2  ABT-737  Calcineurin  Cyclosporine
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Introduction
Bcl-2 (B cell lymphoma 2) is the prototype of an evolu-
tionary conserved family of proteins that regulate the
mitochondrial apoptosis pathway [1, 2]. Aside from its role
as a proto-oncogene [3], Bcl-2 has a fundamental function
in development and in the regulation of cell survival in
different tissues [4]. This is well demonstrated by the
phenotype of Bcl-2 deficient mice, characterized by
accelerated lymphoid apoptosis, polycystic kidneys and
accelerated hair depigmentation [4].
The advent of selective Bcl-2 inhibitors offers unex-
plored opportunities for a pharmacological interaction with
these mechanisms. Because of their limited off-target
effect the small molecule BH3-mimetics ABT-737 [5] and
ABT-263 (Navitoclax) are of notable interest [6]. These
rationally designed BH3-mimetics initiate the mitochondrial
apoptosis cascade by inhibition of the anti-apoptotic Bcl-2
family members Bcl-2, Bcl-XL and Bcl-w [5], induced
apoptosis in several tumor models [7] and represent a
promising class of anti-neoplastic agents [8, 9]. Moreover, in
consideration of the multiple physiological functions of Bcl-
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2, the same agents might find clinical applications in other
settings. In particular, due to the critical role of the intrinsic
apoptosis system in the immune system, Bcl-2 inhibitors
displayed an immuno-modulatory effect and inhibited
autoimmunity [10, 11] and allograft rejection [12, 13].
Lymphocytes tightly regulate the expression of pro- and
anti-apoptotic members of the Bcl-2 family during different
stages of differentiation. Bcl-2 is crucial for survival of naı¨ve
T cells [14], whereas other Bcl-2 family members are critical
in hematopoietic stem cells, in thymocytes, in activated
T cells and in memory cells [15]. The dynamic regulation of
different Bcl-2 protein family members (not all of them
efficiently inhibited by ABT-737) determined the selectivity
profile of ABT-737 on different lymphocyte subpopulations
and eventually its immuno-modulatory properties [16].
Treatment with classical immunosuppressive drugs, such as
calcineurin inhibitors, had a marked impact on the regulation
of the intrinsic apoptosis pathway in T cells after antigen
recognition and significantly increased the immunosup-
pressive effect of ABT-737 [13]. On the other hand, calci-
neurin-deficient mice expressed a lower level of Bcl-2 in
naı¨ve T cells and were characterized by a moderate lym-
phopenia, indicating that Bcl-2 expression in naı¨ve T cells
also depends on the activity of the calcineurin-NFAT path-
way [17]. A similar phenomenon was observed in T cells
isolated from bronchoalveolar lavage fluid in asthmatic
patients treated with cyclosporine A (CsA) [18].
In this study we investigated the effect of a blockade of
the calcineurin/NFAT pathway on the pro-apoptotic
potency of ABT-737 in adult mice. Calcineurin inhibitors
reduced the expression of Bcl-2 in naı¨ve lymphocytes and
increased their sensitivity to ABT-737 in vitro and in vivo.
Interestingly, this synergistic effect was not limited to
lymphatic cells and similarly influenced platelets and
melanocytes. As a result, treatment with ABT-737 and CsA
partially reproduced the phenotype of Bcl-2 deficient mice,
as shown by lymphocyte depletion and hair depigmenta-
tion, but not renal cyst formation.
Methods
Mice
C57BL/6 (B6, H-2b) and Bim knock-out mice (Bim-/-,
H-2b) mice were housed in specific pathogen-free condi-
tions at the University of Zu¨rich. Bim-/- mice were
kindly provided by Andreas Strasser [19]. All experiments
were performed with 6–8 weeks old mice and according to
protocols approved by the legal authority (Veterinary
Office of the Canton of Zu¨rich, Switzerland). Skin trans-
plantation was performed using full thickness back skin
(about 0.5–1.0 cm2) as previously described [13].
Reagents and drugs
ABT-737 was provided by Abbott Bioresearch (Worcester,
USA): for in vitro experiments ABT-737 was dissolved in
DMSO at a concentration of 5 mM and then diluted in culture
medium. For in vivo applications ABT-737 was dissolved in
polyethylene glycol, tween 80, dextrose solution and DMSO
and injected intra-peritoneally (i.p.). CsA was purchased from
Enzo Biochem (Farmingdale, New York, USA), dissolved in
ethanol and cremaphor EL (Sigma-Aldrich, Buchs, Switzer-
land), then diluted in PBS and injected subcutaneously (s.c.) at
10 mg/kg. Tacrolimus (FK506) was purchased from Enzo-
Biochem, the NFAT-inhibitor VIVIT-R from Calbiochem
(Merck, Darmstadt, Germany).
Cell culture
Splenocytes were cultured in RPMI medium containing
10 % fetal bovine serum, penicillin 100 U/mL, strepto-
mycin 100 lg/mL, 2-mercaptoethanol 50 lM. CsA, Tac
and VIVIT-R were added to the medium at the beginning
of the culture. In some experiments, after 48 h of culture
ABT-737 was added and 12 h later cell viability was
assessed by propidium iodide exclusion in FACS.
Fluorescence activated cell sorting (FACS) and blood
analyses
FACS analyses were performed with a BD-FACSCanto
(Becton–Dickinson, Basel, Switzerland). For surface FACS
staining cells were incubated with the required antibodies
in FACS buffer at 4 C for 30 min. For Bcl-2 staining,
after surface staining the cells were permealized by 10 min
incubation in Permeabilization Wash Buffer (Biolegend,
Uithoorn, Netherlands), then incubated with the anti-mouse
Bcl-2 antibody for additional 30 min at room temperature,
according to the manufacturer’s protocol. Anti-mouse
CD3-FITC, CD3-APC, CD4-PE, CD8-APC, CD11b-PE-
Cy7, B220-FITC, B220-PE and propidium iodide (PI) were
purchased from eBioscience (Frankfurt, Gernamy), anti-
mouse CD25-PE/Cy7 from Biolegend (Uithoorn, Nether-
lands), anti-mouse Bcl-2-PE from Becton–Dickinson
(Basel, Switzerland). Hematological analyses were per-
formed in the laboratory of the Division of Hematology at
the University Hospital Zu¨rich with an ADVIA 2120 flow
cytometer (Siemens, Eschborn, Germany).
Histology and immunohistochemistry
Skin and organs were removed, fixed overnight in 10 %
buffered formalin and embedded in parraffin following
routine protocols. Sections of 3 lM thickness were stained
with periodic acid-Schiff (PAS) for routine evaluation.
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Formalin-fixed, paraffin-embedded skin sections were
deparaffinized and rehydrated, then stained with a mouse
monoclonal antibody against S-100 (Abcam, ab4066,
dilution 1:200) after blocking of the unspecific signal with
a goat Fab anti-mouse IgG (Rockland, 810-1102, dilution
1:50). The tissue was then incubated with Dako REALTM
Link, Biotinylated Secondary Antibodies, and with Dako
REALTM Streptavidin Alkaline Phosphatase (AP). The
reaction is visualized by a RED chromogen (Dako RE-
ALTM Detection System, Alkaline Phosphatase/RED,
Rabbit/Mouse Code K5005). Slides were counterstained
with hematoxilin. Conventional kidney histology was
performed as previously described [20].
Statistics
Student t test was used to compare values between groups
as appropriate. Half maximal inhibitory concentration
(IC50)-values were calculated using a log(inhibitor) versus
response model. A linear regression analysis was per-
formed in some experiments. P \ 0.05 was considered
significant. Graph Pad Prism Software Version 5.0 was
used for calculations.
Results
CsA enhances sensitivity to ABT-737 and down-
regulates Bcl-2 in naı¨ve T cells in vitro
The effect of a combined Bcl-2 and calcineurin inhibition
was first assessed on lymphocytes in vitro. Lymphocytes
were isolated from the spleen of naı¨ve 6–8 weeks old mice
and cultured under different concentrations of CsA during
36 h and subsequently treated with ABT-737 for additional
12 h. FACS analysis for cell viability indicated that lower
concentrations of ABT-737 were sufficient to induce
apoptosis in naı¨ve T cells pre-incubated with CsA in a
concentration dependent manner (Fig. 1a). Since the bal-
ance between the anti-apoptotic Bcl-2 and the pro-apop-
totic Bim determines survival of naı¨ve T cells [14], the role
of these two factors in our model was specifically inves-
tigated. The same in vitro experiment was repeated using
splenocytes isolated from Bim-/- mice. According to
previous reports [14], higher concentrations of ABT-737
were required to induce apoptosis in Bim-/- T cells.
However, pre-incubation with CsA similarly increased the
pro-apoptotic potency of ABT-737 on wild type (wt) and
Bim-/- cells, suggesting that this effect is not dependent
on Bim (Fig. 1b). On the other hand, we found that CsA
reduced Bcl-2 expression in viable CD3 positive lympho-
cytes (Fig. 1c). The same effect was measured using the
alternative calcineurin inhibitor FK506 (tacrolimus) and
the NFAT inhibitor VIVIT-R, indicating that this was not
an off-target effect of CsA and that the activity of the
calcineurin-NFAT pathway regulates Bcl-2 expression in
CD4 and CD8 T cells (Fig. 1d). Moreover, down-regula-
tion of Bcl-2 by CsA correlated with a decreased viability
of T cells in culture (Fig. 1e) and with the half maximal
inhibitory concentration of ABT-737 (IC50) required to
induce apoptosis in T cells. Thus, blocking the calcineurin/
NFAT pathway reduced the expression of Bcl-2, and a
synergistic Bcl-2 inhibition was obtained by a combination
of calcineurin inhibitors and BH3-mimetics in vitro.
CsA potentiates the pro-apoptotic effect of ABT-737
on lymphohematopoietic cells in vivo
The synergistic effect of ABT-737 and CsA was further
characterized in vivo. Eight weeks old B6 mice were injected
with ABT-737 (50 mg/kg, i.p.) and/or CsA (10 mg/kg, s.c.)
twice daily during 3 days and then euthanized for FACS
analysis. According to previous reports [12, 13], ABT-737
markedly reduced the number of B and T cells and induced a
moderate thrombocytopenia in blood (Table 1) and in the
spleen (Table 2). CsA had a limited effect on hematological
values as a single agent, but significantly potentiated the
effect of ABT-737 not only on lymphocytes, but also on
platelets, resulting in a severe lymphopenia and thrombo-
cytopenia in the combination group. Among T cells, ABT-
737 was more effective in depleting CD8 than CD4 T cells,
and this effect was even more pronounced in combination
with CsA (Fig. 2). As a consequence, more than 95 % of the
CD8 T cells were depleted in blood and spleen in mice
treated with CsA and ABT-737. Similar results were
obtained in the lymph nodes (data not shown). In contrast,
erythrocytes and neutrophil granulocytes, which are not
affected by ABT-737 and CsA as single agents [13], were
also not depleted in the combination group (Table 1). Thus,
CsA potentiated the effect, but did not alter the selectivity
profile of ABT-737 on lymphatic and hematopoietic cells
and did not induce a generalized myelosuppression.
ABT-737 induces fur depigmentation in synergism
with CsA
Apart from its fundamental role in lymphocytes, Bcl-2
controls survival of melanocyte stem cells [21]. In our
in vivo experiments we observed, that ABT-737 also had
an impact on hair pigmentation. To characterize this phe-
nomenon, B6 mice were shaved and injected s.c. with a
single dose of ABT-737. After hair re-growth an irrevers-
ible depigmentation of the fur was observed in the area
treated with ABT-737, whereas no change was registered
on the contralateral side that had been exposed to DMSO-
containing vehicle (Fig. 3a). A similar process was
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observed after treatment with ABT-737 injected i.p. during
14 days at 50 mg/kg/day. Interestingly, i.p. application
induced depigmentation of the abdominal skin only,
whereas head, chest and back were spared. This particular
pattern suggested that a direct effect of ABT-737 from the
peritoneal cavity was responsible for this process (Fig. 3b).
A similar fur depigmentation was observed in agouti mice
(CBA background), confirming that this was not a strain
specific effect (data not shown). In contrast, hair depig-
mentation was not observed in Bim-/- mice, indicating
that this effect of ABT-737 was strictly dependent on the
presence of an intact intrinsic apoptosis pathway and that
Bim is a critical pro-apoptotic factor in melanocytes
(Suppl. Fig. 1) [22]. Interestingly, the synergism with CsA
influenced also this effect of ABT-737. Simultaneous
treatment with ABT-737 (50 mg/kg/day, i.p.) and CsA
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Fig. 1 Synergistic Bcl-2 inhibition in lymphocytes in vitro. a Spleno-
cytes were incubated with CsA for 36 h, subsequently ABT-737 was
added for additional 12 h of culture. Lower concentrations of ABT-
737 were sufficient to induce apoptosis in cells pre-exposed to CsA
[IC50 and 95 % confidence interval in lM; CsA 0 lM: 0.0034
(0.0025–0.0045); CsA 1 lM: 0.0004 (0.0002–0.0006); CsA 10 lM:
0.0001 (0.00001–0.0002)]. b In the same experimental setting
Bim-/- cells displayed a higher resistance to ABT-737 [IC50
0.1703 lM (0.0782–0.3710)] compared to wt cells [IC50 0.0111 lM
(0.0082–0.015)] but their sensitivity to ABT-737 was also reduced
after pre-incubation with CsA [IC50 after incubation with CsA
10 lM: 0.0380 (0.0236–0.0613]). c, d Inhibition of the calcineurin–
NFAT pathway reduced the expression of Bcl-2 in naı¨ve T cells.
FACS analysis was performed after 48 h of culture in the presence of
the calcineurin inhibitors cyclosporine A (CsA) and tacrolimus
(FK506) or of the NFAT inhibitor VIVIT-R. To selectively
investigate cells, which were still viable before the cell membrane
permeabilitation for intracellular FACS-staining, only FSC high cells
were considered for FACS analysis (s. gating strategy). A represen-
tative example for CD3 positive cells and CsA is shown in histograms
in c (isotype control, CsA 100 and CsA 0 lM). A quantitative
analysis for CD4 and CD8 T cells and the different drugs is presented
in d. e The lower expression of Bcl-2 correlated with a diminished
spontaneous viability of CD8 T cells, as measured by propidium
iodide exclusion in FACS in parallel cultures not exposed to the
permeabilitation process. d Similarly, sensitivity to ABT-737 as
determined by the half maximal inhibitory concentration of ABT-737
for cell viability linearly correlated with the expression of Bcl-2.
Statistical comparison with control; * P \ 0.05, ** P \ 0.01. Each
point was calculated from duplicates and normalized with cultures
exposed to vehicle; the data were confirmed in at least 2 independent
experiments
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(10 mg/kg/day, s.c.) induced an irreversible systemic hair
depigmentation, starting at the site of ABT-737 injection
and progressing to a general hair involvement, whereas
CsA alone did not show any effect (Fig. 3c).
In skin biopsies we observed a marked reduction in the
number of melanocytes in the hair follicles in areas of
depigmentated fur. This effect increased with time, being
more accentuated 14 days after ABT-737 treatment in
comparison to 7 and to 2 days (Fig. 4a). In biopsies taken
200 days after ABT-737 treatment we additionally
observed a reduction in the number as well as in the size of
hair follicles and a dysplastic hair shaft (Fig. 4b). Treat-
ment with CsA alone had no effect on hair pigmentation,
size or morphology. Notably, no inflammatory infiltrates
were observed in skin biopsies. Moreover, transplantation
of normal black B6 skin onto depigmentated B6 mice
resulted in normal black skin pigmentation of the graft
(Suppl. Fig. 2), indicating that depigmentation was the
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Fig. 2 Effect of ABT-737 and
cyclosporine A on T cell
subpopulations in vivo.
Splenocytes were analyzed by
FACS after a 3 day treatment
with ABT-737 (2 9 50 mg/kg/
day) or CsA (2 9 10 mg/kg/
day). Among T cells (CD3?),
we observed a more pronounced
depletion in the CD8 T cell
population in mice treated with
ABT-737. This selectivity was
even more pronounced in
combination with CsA (a),
resulting in an almost complete
depletion of CD8 T cells in the
spleen in the combination group
(b). *** P \ 0.001,
n/group = 5
Table 1 Effect of ABT-737 in combination with cyclosporine A on blood cells
Groups P value
A Vehicle B CsA C ABT-737 D CsA ? ABT-737 A vs. B B vs. D C vs. D
Erythrocytes [1012/L] 9.21 ± 0.24 9.27 ± 0.20 9.60 ± 0.16 9.24 ± 0.51 0.66 0.89 0.28
Leukocytes [109/L] 5.67 ± 0.89 3.37 ± 0.52 1.65 ± 0.59 1.29 ± 0.27 0.001 \0.0001 0.27
CD3 [109/L] 1.33 ± 0.19 1.19 ± 0.26 0.42 ± 0.15 0.22 ± 0.05 0.37 \0.0001 0.03
CD4 [109/L] 0.74 ± 0.13 0.72 ± 0.17 0.31 ± 0.12 0.18 ± 0.04 0.81 0.0001 0.05
CD8 [109/L] 0.50 ± 0.07 0.40 ± 0.09 0.07 ± 0.02 0.02 ± 0.00 0.08 \0.0001 0.002
B220 [109/L] 3.72 ± 0.71 1.77 ± 0.29 0.66 ± 0.18 0.15 ± 0.07 0.0005 \0.0001 0.001
Neutrophils [109/L] 0.48 ± 0.17 0.31 ± 0.10 0.48 ± 0.14 0.62 ± 0.17 0.09 0.009 0.30
Platelets [109/L] 1184 ± 176.8 1214 ± 97.58 540.3 ± 11.85 120.6 ± 30.24 0.75 \0.0001 \0.0001
Treatment: 3 days, 2 injections/day, ABT-737 (2 9 50 mg/kg/day), cyclosporine A (CsA, 2 9 10 mg/kg/day), n = 5
Table 2 Effect of ABT-737 in combination with cyclosporine A on spleen cells
Groups P value
A Vehicle B CsA C ABT-737 D CsA ? ABT-737 A vs. B B vs. D C vs. D
Cells [106/spleen] 145.6 ± 27.1 110.4 ± 16.0 61.0 ± 14.9 38.2 ± 10.2 0.04 \0.0001 0.02
CD3 [106/spleen] 39.1 ± 10.8 31.1 ± 4.2 12.8 ± 3.5 6.4 ± 1.0 0.16 \0.0001 0.004
CD4 [106/spleen] 25.6 ± 7.7 20.0 ± 2.7 9.4 ± 2.7 4.7 ± 0.7 0.16 \0.0001 0.005
CD8 [106/spleen] 9.6 ± 2.2 8.5 ± 1.4 1.7 ± 0.7 0.4 ± 0.1 0.36 \0.0001 0.003
B220 [106/spleen] 93.6 ± 14.7 70.4 ± 12.1 39.2 ± 9.7 22.5 ± 6.1 0.03 \0.0001 0.01
Treatment: 3 days, 2 injections/day, ABT-737 (2 9 50 mg/kg/day), cyclosporine A (CsA, 2 9 10 mg/kg/day), n = 5
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effect of a short-term, direct effect of ABT-737 on mela-
nocytes stem cells and not the result of an autoimmune
(vitiligo-like) disease.
Absence of renal cyst formation in mice treated
with ABT-737 and CsA
Additional effects of ABT-737 in combination with CsA
were investigated by a histological analysis of the most
important internal organs and—in consideration of the
phenotype of Bcl-2 deficient mice—particularly of the kid-
ney. ABT-737 did not increase the number of apoptotic cells
in the kidney in the short term [13], but the effect of a long
exposure to a Bcl-2 inhibitor on renal tissue is not known. In a
first experiment, 6–8 weeks old B6 mice were treated with
ABT-737 alone or in combination with CsA during 14 days
and then observed for more than 200 days (Fig. 5a). In a
second experiment, B6 mice were treated with the same
regime during 50 consecutive days and then euthanized for
histological investigations (Fig. 5b). In both cases the kidney
tissue was normal, no cystic degeneration of the tubuli was
observed and by conventional histology we did not detect
any pathological alterations of the glomerular structure.
Discussion
This study was designed to investigate the effect of a
combined Bcl-2 and calcineurin inhibition with a primary
focus on lymphatic cells. Blocking the calcineurin/NFAT
pathway induced a down-regulation of Bcl-2 in lympho-
cytes and increased their sensitivity to the Bcl-2 inhibitor
ABT-737 in vitro and in vivo. Interestingly, this synergism
was not limited to lymphocytes: mice treated with CsA and
ABT-737 developed a more pronounced thrombocytopenia
and also a generalized hair depigmentation as a result of
melanocyte depletion. These results suggest that calcineu-
rin inhibitors potentiate the pro-apoptotic effect of BH3-
mimetics without altering their selectivity profile.
Previous studies characterized a complex interaction
between the calcineurin/NFAT pathway and the regulation
of apoptosis. Bcl-2 directly influences the activity of cal-
cineurin by a direct molecular interaction, e.g. the nuclear
translocation of NFAT is inhibited when calcineurin forms
a complex with Bcl-2 [23]. On the other hand, the calci-
neurin/NFAT pathway itself is a key regulator of the
apoptosis pathway [24]. Calcineurin directly dephospho-
rylates the anti-apoptotic Bcl-2 [25] and the pro-apoptotic
Bad [26], and activation of the Ca2?/calcineurin/NFAT
pathway regulates the expression of Fas, Bcl-2A1 and
many other pro- and anti-apoptotic factors in activated
T cells [27, 28]. Apart from its essential role in T cell
activation, calcineurin was also required for the homeo-
static survival of T cells, as demonstrated by the Bcl-2
dependent, accelerated spontaneous lymphocyte apoptosis
observed in calcineurin Aß deficient mice [17]. Moreover,
CsA influences mitochondrial permeability in a
Fig. 3 Hair depigmentation
after treatment with ABT-737
and CsA. a B6 mice were
shaved and treated with a single
s.c. injection of ABT-737 on the
right side and of DMSO
containing vehicle in the left
side. After hair re-growth
(3 weeks) we observed a
localized hair depigmentation in
correspondence of the ABT-737
injection. b After 14 daily i.p.
injections with ABT-737
(50 mg/kg/day) a irreversible
depigmentation of the
abdominal fur was observed
(photos: day 200 after
treatment; one representative
individual mouse in three
different views is shown). c In
combination with CsA, this
effect of ABT-737 was
markedly increased, resulting in
a generalized irreversible fur
depigmentation. The same
phenomenon was observed in
more than 50 mice in at least 5
independent experiments
320 Apoptosis (2013) 18:315–323
123
calcineurin-independent manner by interacting with cy-
clophilin D, and may therefore exert a direct pro- or anti-
apoptotic effect [29, 30].
Because of the fundamental role of Bcl-2 in these highly
interconnected and dynamically modulated processes, the
advent of selective Bcl-2 inhibitors opens unexplored
options for pharmacological combinations targeting the
apoptosis pathway. We previously showed that a calci-
neurin-dependent up-regulation of Bcl-2A1 limits the
pro-apoptotic potency of ABT-737 on T cells after antigen-
recognition [16]. Here we show that the synergistic effect
with CsA is not a prerogative of activated T cells. Because
of the critical role of calcineurin for survival of naı¨ve
lymphocytes, CsA potentiated the pro-apoptotic effect of
ABT-737 on B and T cells and induced a marked lym-
phopenia. The reduced Bcl-2 expression measured in
lymphocytes exposed to inhibitors of the calcineurin-
NFAT pathway represents a plausible explanation for this
synergism, but—in consideration of the complexity of
apoptosis regulation—additional molecular and pharma-
cological mechanisms are likely to be involved. In any
case, this observation may be clinically relevant to increase
the anti-neoplastic efficacy of ABT-737 on lymphatic
tumors and to exploit the immuno-modulatory effect of
ABT-737.
The moderate thrombocytopenia previously described
after ABT-737 treatment was significantly increased in
combination with CsA (Table 1) and may represent a rel-
evant side effect in a clinical context. ABT-737 dependent
thrombocytopenia is the result of Bcl-XL inhibition in
platelets and megakaryocytes [31] and CsA enhanced
platelet activation [32]. Further investigations are required
to clarify the synergistic effect of ABT-737 and CsA in this
particular setting.
Survival of melanocyte stem cells depends on Bcl-2. As
a result, the physiological mechanism of hair graying is
accelerated in Bcl-2 deficient mice [33]. The i.p. applica-
tion of ABT-737 reproduced this phenotype by inducing
melanocyte depletion and consequently hair depigmenta-
tion. To our knowledge, this effect of ABT-737 had never
been described before. Moreover, we observed that it was
dramatically increased in combination with CsA. ABT-737
as a single agent was sufficient to induce hair graying at the
site of injection, but that a combination with CsA led to a
generalized depigmentation, suggesting that CsA sensitized
the melanocytic cells to the effect of ABT-737 in a similar
way as we found in lymphocytes. This synergism may be
relevant for the development of new melanoma therapies,
particularly in consideration of previous studies showing an
effect of ABT-737 on melanoma cells [34]. Moreover, the
Fig. 4 Skin histology after ABT-737 treatment. a Skin biopsies were
taken at day 2, 7 and 14 after s.c. injection of ABT-737 (50 mg/kg).
Melanocytes (S-100 positive cells, red, arrows) and pigment (brown)
progressively disappeared after exposure to ABT-737. Bar 100 lM,
n = 3. b In the long term the hair depigmentation was accompanied
by a reduction in the number and in the size of hair follicles, as shown
in skin biopsies taken 200 days after a 2 weeks i.p. treatment with
ABT-737 (50 mg/kg/day) and CsA (10 mg/kg/day). Bar 500 lM,
n = 3 (Color figure online)
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dysplastic alteration of the hair follicle observed in the
long-term after ABT-737-induced melanocyte depletion
may represent an innovative model to investigate the role
of melanocyte stem cells in hair follicle biology.
Bcl-2 deficient mice are characterized by an abnormal
renal development, manifest congenital kidney hypoplasia
with polycystic degeneration and renal failure. Although a
disturbed regulation of DNA-synthesis, apoptosis and cell-
adhesive and migratory properties have been shown in Bcl-
2 deficient renal tubular cells [35, 36], the exact patho-
genesis of this disorder is not known. ABT-737 did not
induce any alteration of the renal structure also after a long
treatment and in combination with CsA, indicating that the
role of Bcl-2 is presumably limited to a defined stadium
during organogenesis [37].
In conclusion, calcineurin and Bcl-2 inhibitors displayed
a potent synergistic effect that may be relevant to exploit
the anti-neoplastic and immuno-modulatory effect of BH3-
mimetics and to further investigate the role of Bcl-2 in
lymphocyte, in the skin and in renal development.
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